The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis.

Authors:
Address: Division of Biological Chemistry and Drug Discovery, Wellcome Trust Biocentre, College of Life Sciences, University of Dundee, Dundee, Scotland, UK.
Journal:


Publication:

abstract

Safer and more effective oral drugs are required to treat visceral leishmaniasis, a parasitic disease that kills 50,000 to 60,000 people each year in parts of Asia, Africa, and Latin America. Here, we report that fexinidazole, a drug currently in phase 1 clinical trials for treating African trypanosomiasis, shows promise for treating visceral leishmaniasis. This 2-substituted 5-nitroimidazole drug is rapidly oxidized in vivo in mice, dogs, and humans to sulfoxide and sulfone metabolites. Both metabolites of fexinidazole were active against Leishmania donovani amastigotes grown in macrophages, whereas The parent compound was inactive. Pharmacokinetic studies with fexinidazole (200 mg/kg) showed that fexinidazole sulfone achieves blood concentrations in mice above the EC(99) (effective concentration inhibiting growth by 99%) value for at least 24 hours after a single oral dose. A once-daily regimen for 5 days at this dose resulted in a 98.4% suppression of infection in a mouse model of visceral leishmaniasis, equivalent to that seen with the drugs miltefosine and Pentostam, which are currently used clinically to treat this tropical disease. In African trypanosomes, the mode of action of nitro drugs involves reductive activation via a NADH (reduced form of nicotinamide adenine dinucleotide)-dependent bacterial-like nitroreductase. Overexpression of the leishmanial homolog of this nitroreductase in L. donovani increased sensitivity to fexinidazole by 19-fold, indicating that a similar mechanism is involved in both parasites. These findings illustrate the potential of fexinidazole as an oral drug therapy for treating visceral leishmaniasis.



Related Articles
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
Antimicrob Agents Chemother. 2...
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
Sokolova AY, Wyllie S, Patterson S, Oza SL, Read KD, Fairlamb AH. Antimicrob Agents Chemother. 2010 Jul; 54(7):2893-900. Epub 2010 May 3.
Genotoxicity profile of fexinidazole--a drug candidate in clinical development for human African trypanomiasis (sleeping sickness).
Mutagenesis. 2012
Genotoxicity profile of fexinidazole--a drug candidate in clinical development for human African trypanomiasis (sleeping sickness).
Tweats D, Bourdin Trunz B, Torreele E. Mutagenesis. 2012 Apr 26; . Epub 2012 Apr 26.
Review Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
J Assoc Physicians India. 2003
Review Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
Sangraula H, Sharma KK, Rijal S, Dwivedi S, Koirala S. J Assoc Physicians India. 2003 Jul; 51:686-90.
Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis.
Antimicrob Agents Chemother. 2...
Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis.
Smith AC, Yardley V, Rhodes J, Croft SL. Antimicrob Agents Chemother. 2000 Jun; 44(6):1494-8.
Review Advances in the treatment of leishmaniasis.
Curr Opin Infect Dis. 2002
Review Advances in the treatment of leishmaniasis.
Sundar S, Rai M. Curr Opin Infect Dis. 2002 Dec; 15(6):593-8.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.